Congenital CMV

From IDWiki
Revision as of 18:05, 11 August 2019 by Maintenance script (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Congenital CMV

Epidemiology

  • Risk of transmission to fetus
    • Primary infection: 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
    • Non-primary
      • Reinfection: 5% risk
      • Reactivation: 1% risk

Clinical Presentation

  • At birth
    • Microcephaly
    • Periventricular calcifications
    • Chorioretinitis
    • Sensorineural hearing loss
    • Optic nerve atrophy
    • Hepatosplenomegaly
    • Cytopenia
  • Later
    • Cognitive deficits (7%)
    • Sensorineural hearing loss (20%)

Diagnosis

  • In mom, IgM antibodies
  • In baby, urine PCR within 2 weeks of birth

Management

  • Treatment is indicated for symptomatic babies
    • Brain
    • Hearing
    • Eye
  • IV ganciclovir or PO valganciclovir, for 6 months
  • Monitor CBC while on therapy

n c

References

  1. ^  Gisela Enders, Anja Daiminger, Ursula Bäder, Simone Exler, Martin Enders. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. Journal of Clinical Virology. 2011;52(3):244-246. doi:10.1016/j.jcv.2011.07.005.